A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-11-23. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 16.3% (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: amlleukemiatherapytumordocumented
  Phrases that lowered it: lung cancercell lungsmall cellopen labeltrial
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past trials: 1552 (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 24.3% (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 192 (lowers risk) · Sponsor's track record
• Number of arms: 16 (lowers risk) · Design
• Drug's FAERS reports marked serious: 95.6% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Keywords listed: 30 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 10077 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 38210 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Disease area, respiratory: Yes (raises risk) · Disease area
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers NCT02367196 · started 2015 · scored riskier than 53% of active trials completed
• A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab NCT01307267 · started 2011 · scored riskier than 96% of active trials completed
• PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies NCT05107856 · started 2022 · scored riskier than 57% of active trials terminated
• A Study of PRT1419 in Patients With Advanced Solid Tumors NCT04837677 · started 2021 · scored riskier than 54% of active trials completed
• Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. NCT04881045 · started 2021 · scored riskier than 82% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.